TrialsgrambetaRCTs are beautiful

FOURIER

2017

Further Cardiovascular Outcomes Research with PCSK9 Inhibition

In 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.

Result

Efficacy: Composite CV eventsHR 0.85 (95% CI 0.79-0.92) · P < 0.001

Below 1 favours evolocumab, above 1 favours placebo.

Event rates
Absolute difference
1.5 points
NNT
67

Absolute difference and NNT are derived from the event rates.

Also reported: Median LDL 30 mg/dL.

Original publication
Subtopic
PCSK9i
Design
Double-blind RCT, median 2.2 yr
Relevance
Important: one of several pillars.
Source
Sabatine MS, et al. N Engl J Med. 2017;376(18):1713-1722.doi 10.1056/NEJMoa1615664

Discussion & critique

Short follow-up may underestimate effect: extended follow-up suggests larger benefit over time. Cost-effectiveness limits broad uptake; reserved for highest-risk patients.

Discussed in podcasts